Company profile IMRX
After 39 days of this quarter the interest is at 17.0. Based on that we can calculate that during remaining 52 days it will total up to 40.0. Immuneering expected interest is significantly lower compared to previous quarter (-75.5%) and same quarter last year (-82.5%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 59 | 78 32.2% QoQ | 184 135.9% QoQ | 93 -49.5% QoQ |
| 2020 | 129 118.6% YoY 38.7% QoQ | 115 47.4% YoY -10.9% QoQ | 188 2.2% YoY 63.5% QoQ | 63 -32.3% YoY -66.5% QoQ |
| 2021 | 30 -76.7% YoY -52.4% QoQ | 127 10.4% YoY 323.3% QoQ | 302 60.6% YoY 137.8% QoQ | 120 90.5% YoY -60.3% QoQ |
| 2022 | 159 430.0% YoY 32.5% QoQ | 74 -41.7% YoY -53.5% QoQ | 233 -22.8% YoY 214.9% QoQ | 140 16.7% YoY -39.9% QoQ |
| 2023 | 228 43.4% YoY 62.9% QoQ | 295 298.6% YoY 29.4% QoQ | 71 -69.5% YoY -75.9% QoQ | 163 16.4% YoY 129.6% QoQ |
| 2024 | 17 -92.5% YoY -89.6% QoQ | - | - | - |
The average 5 years interest of Immuneering was 10.99 per week. The last year interest of Immuneering compared to the last 5 years has changed by 24.02%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 41.54%.
There is not enough data for Immuneering ticker to provide analysis
There is not enough data for Immuneering ticker to provide correlation calculation
There is not enough data for Immuneering ticker to provide analysis
After 39 days of this quarter the interest is at 100.0. Based on that we can calculate that during remaining 52 days it will total up to 233.0. Immuneering stock expected interest is significantly higher compared to previous quarter (+180.7%) and same quarter last year (+82.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 68 | 67 -1.5% QoQ | 74 10.4% QoQ | 35 -52.7% QoQ |
| 2020 | 69 1.5% YoY 97.1% QoQ | 85 26.9% YoY 23.2% QoQ | 72 -2.7% YoY -15.3% QoQ | 48 37.1% YoY -33.3% QoQ |
| 2021 | 58 -15.9% YoY 20.8% QoQ | 0 -100.0% YoY -100.0% QoQ | 161 123.6% YoY inf% QoQ | 24 -50.0% YoY -85.1% QoQ |
| 2022 | 43 -25.9% YoY 79.2% QoQ | 178 inf% YoY 314.0% QoQ | 209 29.8% YoY 17.4% QoQ | 159 562.5% YoY -23.9% QoQ |
| 2023 | 128 197.7% YoY -19.5% QoQ | 79 -55.6% YoY -38.3% QoQ | 125 -40.2% YoY 58.2% QoQ | 83 -47.8% YoY -33.6% QoQ |
| 2024 | 100 -21.9% YoY 20.5% QoQ | - | - | - |
The average 5 years interest of Immuneering stock was 7.15 per week. The last year interest of Immuneering stock compared to the last 5 years has changed by 25.03%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 74.27%.
There is not enough data for IMRX cancer treatment to provide analysis
There is not enough data for IMRX cancer treatment to provide correlation calculation
There is not enough data for IMRX cancer treatment to provide analysis
There is not enough data for IMRX clinical trials to provide analysis
There is not enough data for IMRX clinical trials to provide correlation calculation
There is not enough data for IMRX clinical trials to provide analysis
There is not enough data for IMRX dual-MEK inhibitor to provide analysis
There is not enough data for IMRX dual-MEK inhibitor to provide correlation calculation
There is not enough data for IMRX dual-MEK inhibitor to provide analysis
There is not enough data for IMRX solid tumor treatment to provide analysis
There is not enough data for IMRX solid tumor treatment to provide correlation calculation
There is not enough data for IMRX solid tumor treatment to provide analysis
There is not enough data for Immuneering medicines to provide analysis
There is not enough data for Immuneering medicines to provide correlation calculation
There is not enough data for Immuneering medicines to provide analysis
There is not enough data for Immuneering oncology to provide analysis
There is not enough data for Immuneering oncology to provide correlation calculation
There is not enough data for Immuneering oncology to provide analysis
There is not enough data for IMRX contact information to provide analysis
There is not enough data for IMRX contact information to provide correlation calculation
There is not enough data for IMRX contact information to provide analysis